Nacev, Benjamin A.

The expanding landscape of ‘oncohistone’ mutations in human cancers

Nacev, B. A., Feng, L., Bagert, J. D., Lemiesz, A. E., Gao, J., Soshnev, A. A., Kundra, R., Schultz, N., Muir, T. W., & Allis, C. D. (2019) · Nature

Chromatin Remodeling and CancerGenomics and Chromatin Dynamics

Cited by 384

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 232

Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis

Head, S. A., Shi, W. Q., Yang, E. J., Nacev, B. A., Hong, S. Y., Pasunooti, K. K., Li, R.-J., Shim, J. S., & Liu, J. O. (2017) · ACS Chemical Biology

PI3K/AKT/mTOR signaling in cancerCancer, Lipids, and Metabolism

Cited by 82

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 60

A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma

Angeles, C. V., Velez, A., Rios, J., Laxa, B., Shum, D., Ruiz, P. D., Shen, Y., Ostrovnaya, I., Gularte-Mérida, R., Nacev, B. A., et al. (2022) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 13